AstraZeneca receives $1.2bn to scale-up and deliver Oxford’s COVID-19 vaccine, antibody testing gains momentum as a deal is struck between Roche and the NHS and details start to emerge on the future of the UK’s relationship with the EU.
Last month, UK government approached Medicines Discovery Catapult, based at Alderley Park, to coordinate the establishment of the national megalabs for the testing of COVID-19.
Commenting on the NIHR 'Framework for restart' released today, Steve Bates OBE, Chief Executive of the BIA said:
Pharmaceutical, healthcare and biotech companies are at the forefront of the COVID-19 response, from therapeutic drug trials and vaccine development to the production of personal protective equipment (PPE) and ventilators.
Commenting on the Government’s approach to the Northern Ireland Protocol released yesterday, Steve Bates OBE, Chief Executive of the BioIndustry Association said:
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This kit is for research use only and launched under the T-SPOT Discovery brand. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner.
A new support fund for innovative firms struggling to access equity finance during the COVID-19 disruption has opened for applications today (20 May). The Future Fund, run by the British Business Bank, will provide convertible loans of between £125,000 and £5m to businesses if they can also secure matched funding from third-party investors.
Commenting on the publication of draft UK-EU free trade agreement text released today Steve Bates OBE, Chief Executive of the BIA said:
Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, announced that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield